Realheart Performs a Directed Issue to EIC in Connection With the Completed Rights Issue

Press Release July 26, 2023

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES.

Scandinavian Real Heart AB ("Realheart" or the "Company") announces that the Company's board of directors, based on the authorization from the annual general meeting on June 14, 2023, has resolved to issue 9 150 000 units to the European Innovation Council ("EIC") Accelerator, in accordance with the investment agreement announced on May 15, 2023. The directed issue consists of 9 150 000 units of the same type and on the same terms as the units in the rights issue announced on the same day and Realheart thus receives an additional SEK 14 640 000 before transaction costs. After the directed issue, the total number of shares will increase from 78 694 446 shares (after registration of the rights issue and the directed issue to underwriters) with 18 300 000 shares to a total of 96 994 446 shares. The EIC will then hold 18,9 of total shares and votes in the company.

The Company had received subscription commitments from EIC based on the following conditions:

- The investment is a co-investment with new and existing shareholders.

- That the investment corresponds to one third of the total capital raising, i.e. the rights issue and the directed issue combined, but that EIC's total ownership does not exceed 20 percent of the company after the investment has been completed.

Through the directed issue to EIC the Company's share capital increases by SEK 1 830 000.0 from SEK 7 869 444.60 after the rights issue and the directed issue to underwriters to SEK 9 699 444.60. Through the directed issue to EIC 9 150 000 warrants of series TO2 are also issued, which entitle the holder to subscribe for 4 575 000 shares in the Company. Upon full exercise of the Warrants, the share capital will increase by a maximum of SEK 457 500.0 and the number of shares will increase by a maximum of 4 575 000 shares.

Total increase in number of shares and share capital

In total the number of shares in Realheart after the rights issue, the directed issue to the underwriters and the directed issue to EIC (jointly the "Issues") increases by 62 015 198 shares from 34 979 248 shares to 96 994 446 shares, and the share capital increases by SEK 6 201 519.80 from SEK 3 497 924.8 to SEK 9 699 444.60. This gives a dilution effect of approximately 63.9 percent of the votes and capital in the Company.

Through the Issues, a total of 31 007 599 warrants of series TO2 are issued, which entitle the holders to subscribe for a maximum of 15 503 799 shares in the Company. Upon full exercise of the warrants, the share capital will increase by an additional maximum of SEK 1 550 379.90. This corresponds to a dilution effect from the Warrants of an additional maximum of approximately 13.8 percent of the votes and capital in the Company.

Advisers

Skills Corporate Finance Nordic AB is financial adviser and Setterwalls Advokatbyrå AB is legal adviser to Realheart in connection with the Rights Issue.

Important information

Publication, release, or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction.

The information in this press release neither contains nor constitutes an offer to acquire, subscribe for or otherwise trade shares, warrants or other securities in Realheart. No action has been taken and no action will be taken to allow an offer to the public in any jurisdiction other than Sweden. The Swedish Financial Supervisory Authority's approval of the Prospectus shall not be construed as an approval of the Company's shares, warrants or other securities. However, this press release is not a prospectus within the meaning of the Prospectus Regulation (EU) 2017/1129 ("Prospectus Regulation"), and this press release neither identifies nor purports to identify risks (direct or indirect) that may be associated with an investment in shares, warrants or other securities in Realheart. The information in this press release is only intended to describe the background to the Rights Issue and does not claim to be complete or exhaustive. No assurance shall be given with respect to the accuracy or completeness of the information in this press release. Any investment decision should, in order for an investor to fully understand the potential risks and benefits associated with the decision to participate in the Rights Issue, be based solely on the information in the Prospectus. Therefore, an investor is recommended to read the entire Prospectus. This press release constitutes marketing in accordance with Article 2(k) of the Prospectus Regulation.

The information in this press release may not be published, released or distributed, directly or indirectly, in or to the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such action would be unlawful, subject to legal restrictions or require other actions than those following from Swedish law. Actions in violation of this instruction may constitute violations of applicable securities laws. No shares, warrants or other securities in Realheart have been registered, and no shares, warrants or other securities will be registered, under the then-applicable United States Securities Act of 1933 (the "Securities Act") or securities legislation in any state or other jurisdiction in the United States, and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States except in accordance with an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with securities legislation in the relevant state or other jurisdiction in the United States.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.